Long-term administration of the dopamine D3/2 receptor agonist pramipexole increases dopamine and serotonin neurotransmission in the male rat forebrain

Journal of Psychiatry and Neuroscience

Volumn 37, Issue 2, 2012, Pages 113-121

  Chernoloz, Olga ^a   El Mansari, Mostafa ^a   Blier, Pierre ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; PRAMIPEXOLE; SEROTONIN; SEROTONIN RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ELECTROPHYSIOLOGY; FOREBRAIN; IN VIVO STUDY; MALE; NERVE CELL; NEUROTRANSMISSION; NONHUMAN; PREFRONTAL CORTEX; RAT; TREATMENT DURATION;

EID: 84857556511     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.110038     Document Type: Article

References (73)

1. Guttman M, Jaskolka J. The use of pramipexole in Parkinson's disease: Are its actions D3 mediated? Parkinsonism Relat Disord 2001;7:231-4.
2. Piercey MF. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol 1998;21:141-51.
3. Reichmann H, Odin P, Brecht HM, et al. Changing dopamine agon ist treatment in Parkinson's disease: experiences with switching to pramipexole. J Neural Transm Suppl 2006;(71):17-25.
4. Corrigan MH, Denahan AQ, Wright EC, et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000;11:58-65.
5. Lattanzi L, Dell'Osso L, Cassano P, et al. Pramipexole in treatmentresistant depression: a 16-week naturalistic study. Bipolar Disord. 2002;4:307-314.
6. Sporn J, Ghaemi SN, Sambur MR, et al. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann Clin Psychiatry 2000;12:137-40.
7. Cassano P, Lattanzi L, Soldani F, et al. Pramipexole in treatmentresistant depression: an extended follow-up. Depress Anxiety 2004; 20:131-8.
8. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004;161:564-6.
9. Bennett JP Jr, Piercey MF. Pramipexole - a new dopamine agonist for the treatment of Parkinson's disease. J Neurol Sci 1999;163:25-31.
10. Tandberg E, Larsen JP, Aarsland D, et al. The occurrence of depression in Parkinson's disease: a community-based study. Arch Neurol 1996;53:175-9.
11. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007;64:327-37.
12. Brocco M, Dekeyne A, Papp M, et al. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors. Behav Pharmacol 2006;17:559-72.
13. Izumi T, Inoue T, Kitagawa N, et al. Open pergolide treatment of tricyclic and heterocyclic antidepressant-resistant depression. J Affect Disord 2000;61:127-32.
14. Muscat R, Papp M, Willner P. Antidepressant-like effects of dopamine agonists in an animal model of depression. Biol Psychiatry 1992;31:937-46.
15. Waehrens J, Gerlach J. Bromocriptine and imipramine in endogenous depression. A double-blind controlled trial in outpatients. J Affect Disord 1981;3:193-202.
16. Mah L, Zarate CA, Nugent AC, et al. Neural mechanisms of antidepressant efficacy of the dopamine receptor agonist pramipexole in treatment of bipolar depression. Int J Neuropsychopharmacol 2011; 14:545-51.
17. Rizzo V, Aricò I, Mastroeni C, et al. Dopamine agonists restore cortical plasticity in patients with idiopathic restless legs syndrome. Mov Disord 2009;24:710-5.
18. Hiramoto T, Kanda Y, Satoh Y, et al. Dopamine D2 receptor stimulation promotes the proliferation of neural progenitor cells in adult mouse hippocampus. Neuroreport 2007;18:659-64.
19. Höglinger GU, Rizk P, Muriel MP, et al. Dopamine depletion impairs precursor cell proliferation in Parkinson's disease. Nat Neurosci 2004;7:726-35.
20. Czéh B, Simon M, Schmelting B, et al. Astroglial plasticity in the hippocampus is affected by chronic psychosocial stress and concomitant fluoxetine treatment. Neuropsychopharmacology 2006;31: 1616-26.
21. McEwen BS, Magarinos AM. Stress and hippocampal plasticity: implications for the pathophysiology of affective disorders. Hum Psychopharmacol 2001;16(Suppl 1):S7-19.
22. Radley JJ, Rocher AB, Rodriguez A, et al. Repeated stress alters dendritic spine morphology in the rat medial prefrontal cortex. J Comp Neurol 2008;507:1141-50.
23. Drevets WC. Prefrontal cortical-amygdalar metabolism in major depression. Ann N Y Acad Sci 1999;877:614-37.
24. Drevets WC, Videen TO, Price JL, et al. A functional anatomical study of unipolar depression. J Neurosci 1992;12:3628-41.
25. Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med 2001;7:541-7.
26. Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003;301:805-9.
27. Chernoloz O, El Mansari M, Blier P. Sustained administration of pramipexole modifies the spontaneous firing of dopamine, norepinephrine, and serotonin neurons in the rat brain. Neuropsychopharmacology 2009;34:651-61.
28. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 2nd ed. San Diego (CA): Academic Press; 1986.
29. Sesack SR, Bunney BS. Pharmacology of dopamine-induced electrophysiological responses in the rat prefrontal cortex: D1- or D2- mediated? Ann N Y Acad Sci 1988;537:529-30.
30. Ranck JB. Behavioral correlates and firing repertoires of neurons in the dorsal hippocampal formation and septum of unrestrained rats. In: Isaacson RC, Pribram KH editors. The hippocampus. New York (NY): Plenum; 1975. p. 207-44.
31. Kandel ER, Spencer WA. Electrophysiology of hippocampal neurons. II. After-potentials and repetitive firing. J Neurophysiol 1961; 24: 243-59.
32. Au-Young SMW, Shen H, Yang CR. Medial prefrontal cortical output neurons to the ventral tegmental area (VTA) and their responses to burst-patterned stimulation of the VTA: neuroanatomical and in vivo electrophysiological analyses. Synapse 1999;34: 245-55.
33. Godbout R, Mantz J, Pirot S, et al. Inhibitory influence of the mesocortical dopaminergic neurons on their target cells: electrophysiological and pharmacological characterization. J Pharmacol Exp Ther 1991;258:728-38.
34. Floresco SB, Grace AA. Gating of hippocampal-evoked activity in prefrontal cortical neurons by inputs from the mediodorsal thalamus and ventral tegmental area. J Neurosci 2003;23:3930-43.
35. Bannon MJ, Wolf ME, Roth RH. Pharmacology of dopamine neurons innervating the prefrontal cingulate and piriform cortices. Eur J Pharmacol 1983;92:119-25.
36. Chaput Y, Blier P, De Montigny C. In vivo electrophysiological evidence for the regulatory role of autoreceptors on serotonergic terminals. J Neurosci 1986;6:2796-801.
37. Chaput Y, Blier P, De Montigny C. In vivo electrophysiological evidence for the regulatory role of autoreceptors on serotonergic terminals. J Neurosci 1986;6:2796-801.
38. Bunney BS, Aghajanian GK. Dopamine and norepinephrine innervated cells in the rat prefrontal cortex: pharmacological differentiation using microiontophoretic techniques. Life Sci 1976;19:1783-9.
39. Ferron A, Thierry AM, Le Douarin C, et al. Inhibitory influence of the mesocortical dopaminergic system on spontaneous activity or excitatory response induced from the thalamic mediodorsal nucleus in the rat medial prefrontal cortex. Brain Res 1984;302:257-65.
40. Thierry AM, Le Douarin C, Penit J. Variation in the ability of neuroleptics to block the inhibitory influence of dopaminergic neurons on the activity of cells in the rat prefrontal cortex. Brain Res Bull 1986;16:155-60.
41. Mantz J, Godbout R, Pirot S, et al. Inhibitory effects of mesocortical dopaminergic neurons on their target cells: electrophysiological and pharmacological characterization. Neurochem Int 1992;20 Suppl:251S-254S.
42. Haddjeri N, Blier P, De Montigny C. Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT(1A) receptors. J Neurosci 1998;18:10150-6.
43. Marchais D, Tassin JP, Bockaert J. Dopaminergic component of [3H]spiroperidol binding in the rat anterior cerebral cortex. Brain Res 1980;183:235-40.
44. Bockaert J, Tassin JP, Thierry AM. Characteristics of dopamine and ß adrenergic sensitive adenylate cyclases in the frontal cerebral cortex of the rat. Comparative effects of neuroleptics on frontal cortex and striatal dopamine sensitive adenylate cyclases. Brain Res 1977;122:71-86.
45. Seamans JK, Yang CR. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 2004;74:1-58.
46. Gorelova N, Seamans JK, Yang CR. Mechanisms of dopamine activation of fast-spiking interneurons that exert inhibition in rat prefrontal cortex. J Neurophysiol 2002;88:3150-66.
47. Gulledge AT, Jaffe DB. Dopamine decreases the excitability of layer V pyramidal cells in the rat prefrontal cortex. J Neurosci 1998; 18:9139-51.
48. Neve KA, Seamans JK, Trantham-Davidson H. Dopamine receptor signaling. J Recept Signal Transduct Res 2004;24:165-205.
49. Santiago M, Machado A, Cano J. Regulation of prefrontal cortical dopamine release by dopamine receptor agonists and antagonists. Eur J Pharmacol 1993;239:83-91.
50. Robbins TW. From arousal to cognition: the integrative position of the prefrontal cortex. Prog Brain Res 2000;126:469-83.
51. Berridge CW, Espana RA, Stalnaker TA. Stress and coping: asymmetry of dopamine efferents within the prefrontal cortex. In: Hugdahl K, Davidson RJ, editors. The asymmetryical brain. Cambridge (MA): MIT Press; 2003. p. 69-104.
52. Deutch AY, Roth RH. The determinants of stress-induced activation of the prefrontal cortical dopamine system. Prog Brain Res 1990; 85:367-402; discussion 402-3.
53. Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct 2008;213:93-118.
54. Drevets WC. Prefrontal cortical-amygdalar metabolism in major depression. Ann N Y Acad Sci 1999;877:614-37.
55. Mayberg HS, Liotti M, Brannan SK, et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry 1999;156:675-82.
56. Kennedy SH, Evans KR, Krüger S, et al. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry 2001;158:899-905.
57. Mayberg HS, Brannan SK, Tekell JL, et al. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry 2000;48:830-43.
58. Stefurak T, Mahurin R, Soloman D. Response specific regional metab olism changes with fluoxetine treatment in depressed Parkinson's patients. Mov Disord 2001;16(Suppl 1):S39.
59. Piñeyro G, Blier P. Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol Rev 1999;51:533-91.
60. El Mansari M, Ghanbari R, Janssen S, et al. Sustained administration of bupropion alters the neuronal activity of serotonin, norepinephrine but not dopamine neurons in the rat brain. Neuropharmacology 2008;55:1191-8.
61. Manta S, Dong J, Debonnel G, et al. Enhancement of the function of rat serotonin and norepinephrine neurons by sustained vagus nerve stimulation. J Psychiatry Neurosci 2009;34:272-80.
62. Chernoloz O, El Mansari M, Blier P. Electrophysiological studies in the rat brain on the basis for aripiprazole augmentation of antidepressants in major depressive disorder. Psychopharmacology (Berl) 2009;206:335-44.
63. Ferré S, Artigas F. Dopamine D2 receptor-mediated regulation of serotonin extracellular concentration in the dorsal raphe nucleus of freely moving rats. J Neurochem 1993;61:772-5.
64. Haj-Dahmane S. D2-like dopamine receptor activation excites rat dorsal raphe 5-HT neurons in vitro. Eur J Neurosci 2001;14:125-34.
65. Aman TK, Shen RY, Haj-Dahmane S. D2-like dopamine receptors depolarize dorsal raphe serotonin neurons through the activation of nonselective cationic conductance. J Pharmacol Exp Ther 2007; 320:376-85.
66. Nestler EJ, Carlezon WA Jr. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 2006;59:1151-9.
67. Swerdlow NR, Koob GF. Dopamine, schizophrenia, mania, and depression: toward a unified hypothesis of cortico-striato-pallidothalamic function. Behav Brain Sci 1987;10:197-245.
68. Mayberg HS. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bull 2003;65:193-207.
69. Anand A, Li Y, Wang Y, et al. Activity and connectivity of brain mood regulating circuit in depression: a functional magnetic resonance study. Biol Psychiatry 2005;57:1079-88.
70. Bench CJ, Friston LKJ, Brown RG, et al. Regional cerebral blood flow in depression measured by positron emission tomography: the relationship with clinical dimensions. Psychol Med 1993;23: 579-90.
71. Drevets WC. Orbitofrontal cortex function and structure in depression. Ann N Y Acad Sci 2007;1121:499-527.
72. Drevets WC, Bogers W, Raichle ME. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur Neuropsychopharmacol 2002;12:527-44.
73. Lozano AM, Mayberg HS, Giacobbe P, et al. Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. Biol Psychiatry 2008;64:461-7.